http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
AlGaN-based deep ultraviolet light-emitting diodes on nanopatterned AlN/sapphire substrates
Donghyun LEE,Jong Won LEE,Jeonghwan JANG,In-Su SHIN,Lu JIN,Jungsub KIM,Jinsub LEE,Hye-Seok NOH,Yong-Il KIM,Youngsoo PARK,Gun-Do LEE,Yongjo PARK,Jong Kyu KIM,Euijoon YOON 한국진공학회 2016 한국진공학회 학술발표회초록집 Vol.2016 No.8
Lee, Hwa Dong,Lee, Won‐,Hee,Roh, Eunmiri,Seo, Chang‐,Seob,Son, Jong‐,Keun,Lee, Seung Ho,Hwang, Bang Yeon,Jung, Sang‐,Hun,Han, Sang‐,Bae,Kim, Youngsoo Blackwell Publishing Ltd 2011 Experimental dermatology Vol.20 No.9
<P><B>Abstract: </B> Microphthalmia‐associated transcription factor (MITF) is inducible in response to cAMP through the cAMP‐responsive element–binding protein (CREB) and plays a pivotal role in the melanocyte‐specific expression of tyrosinase or tyrosinase‐related proteins (TRPs) for melanin biosynthesis. Manassantin A from <I>Saururus chinensis</I> inhibits cAMP‐induced melanin production in B16 melanoma cells. Here, we focused on molecular basis of the antimelanogenic activity. Manassantin A consistently inhibited the cAMP elevator 3‐isobutyl‐1‐methylxanthine (IBMX)‐ or dibutyryl cAMP‐induced melanin production in B16 cells or in melan‐a melanocytes by down‐regulating the expression of <I>tyrosinase</I> or <I>TRP1</I> gene. Moreover, manassantin A suppressed MITF induction through IBMX‐activated CREB pathway, directly inhibiting the Ser‐133 phosphorylation of CREB. However, manassantin A did not affect IBMX‐increased cAMP levels in these cells but also other cAMP‐dependent melanogenic pathways through post‐translational modifications of MITF. This putative molecular mechanism of manassantin A in the inhibition of melanin production suggests its pharmacological potential in skin hyperpigmentation.</P>
Lee, Youngsoo 한국산업정보응용수학회 1998 한국산업정보응용수학회 Vol.2 No.2
In this paper we define the entropy rate and stationary Markov chain and we show the monotonicity of entropy per element and prove that the random tree T_(n) grows linearly with n.
Lee, Sangkyu,Jo, Insu,Kang, Sangmin,Jang, Bongchul,Moon, Joonhee,Park, Jong Bo,Lee, Soochang,Rho, Sichul,Kim, Youngsoo,Hong, Byung Hee American Chemical Society 2017 ACS NANO Vol.11 No.6
<P>Recently, smart contact lenses with electronic circuits have been proposed for various sensor and display applications where the use of flexible and biologically stable electrode materials is essential. Graphene is an atomically thin carbon material with a two-dimensional hexagonal lattice that shows outstanding electrical and mechanical properties as well as excellent biocompatibility. In addition, graphene is capable of protecting eyes from electromagnectic (EM) waves that may cause eye diseases such as cataracts. Here, we report a graphene-based highly conducting contact lens platform that reduces the exposure to EM waves and dehydration. The sheet resistance of the graphene on the contact lens is as low as 593 Omega/sq (+/- 9.3%), which persists in an wet environment. The EM wave shielding function of the graphene-coated contact lens was tested on egg whites exposed to strong EM waves inside a microwave oven. The results show that the EM energy is absorbed by graphene and dissipated in the form of thermal radiation so that the damage on the egg whites can be minimized. We also demonstrated the enhanced dehydration protection effect of the graphene-coated lens by monitoring the change in water evaporation rate from the vial capped with the contact lens. Thus, we believe that the graphene-coated contact lens would provide a healthcare and bionic platform for wearable technologies in the future.</P>
Lee Youngsoo,김명은,남동호 대한천식알레르기학회 2021 Allergy, Asthma & Immunology Research Vol.13 No.5
Purpose: Dupilumab is recommended to be administered biweekly to treat adult patients with moderate-to-severe atopic dermatitis (AD). Real clinical practice data on the clinical efficacy of monthly dupilumab therapy are limited. We analyzed real clinical practice data on the clinical efficacy of monthly dupilumab therapy and predictive markers for favorable clinical responses to the therapy. Methods: Medical records of 57 adult patients with moderate-to-severe AD who received dupilumab therapy every 4 weeks for 16 weeks were analyzed retrospectively. Eczema Area and Severity Index (EASI) were recorded at baseline and week 16. Clinical responses to monthly dupilumab therapy were defined as the proportion of patients with decreased EASI scores of at least 50% or 75% from baseline at week 16 (EASI-50 or EASI-75). Blood eosinophil counts and serum lactate dehydrogenase (LDH) levels were measured at baseline and week 16. Results: Monthly dupilumab therapy showed EASI-50 and EASI-75 clinical responses in 48 (84.2%) and 27 (47.4%) of 57 patients at week 16, respectively. The percentage decrease in EASI scores from baseline at week 16 was significantly inversely correlated with baseline blood eosinophil count (correlation coefficient [r] = −0.405, P = 0.002) and baseline serum LDH level (r = −0.466, P < 0.001). The EASI-75 response rate was higher in patients with low (< 500/μL, 73.3%) than in those with high (≥ 500/μL, 37.5%) baseline blood eosinophil counts (P = 0.032), and was higher in patients with low (< 400 U/L, 55.6%) than those with high (≥ 400 U/L, 10.0%) baseline serum LDH levels (P = 0.013). Conclusions: Monthly dupilumab therapy was clinically effective in adult patients with moderate-to-severe AD in real clinical practice. Baseline blood eosinophil count and serum LDH level could be predictive markers for clinical response to dupilumab therapy.
Clinical Application of Eritoran as Drug Candidate for Sepsis Treatment
Youngsoo Kim, Sun Hong Park, Kiho Lee, Hwa Kyung Lim, Sang-Bae Han 충북대학교 동물의학연구소 2011 Journal of Biomedical and Translational Research Vol.12 No.1
Sepsis is a clinical syndrome defined as a systemic inflammatory response to infection. Eritoran is a synthetic lipid A derivative that competes with lipopolysaccharide in binding to the identical site of myeloid differentiation-2/toll-like receptor 4 complex. Eritoran is effective in decreasing the septic mortality of Gram-negative bacteria-infected animals. Eritoran has been highlighted as a candidate drug for treatment of endotoxemia in phase I clinical studies with healthy human volunteers. A phase II trial of eritoran has been conducted in patients with severe sepsis. Intravenous infusion of eritoran reduced the mortality rate, as compared with the placebo group, in sepsis patients at a high risk of mortality according to acute physiology and chronic health evaluation-II scores. A phase III study of eritoran was completed in 2011. The results appear to be disappointing as no statistically significant difference in all-cause mortality was observed between the eritoran treatment group and the placebo group on day 28 in sepsis patients with a high risk of death. In this review, we focus on the rationale for the use of eritoran in treatment of sepsis as well as its clinical applications.
Lee, Heeju,Kim, Kunhee,Woo, Jeong‐,Jun,Jun, Doo‐,Jin,Park, Youngsoo,Kim, Yunsoo,Lee, Hong Won,Cho, Yong Jai,Cho, Hyun Mo WILEY‐VCH Verlag 2011 Chemical vapor deposition Vol.17 No.7
<P><B>Abstract</B></P><P>Thin films of gallium oxide (Ga<SUB>2</SUB>O<SUB>3</SUB>) are prepared by using a new gallium precursor, dimethylgallium isopropoxide (DMGIP), employing both atomic layer deposition (ALD) and metal‐organic (MO)CVD. The gallium precursor DMGIP, a gallium analogue of dimethylaluminum isopropoxide (DMAIP) that has been successfully used for MOCVD and ALD of aluminum oxide, is likewise a non‐pyrophoric liquid at room temperature with a reasonably high vapor pressure. Using water as the oxygen source, DMGIP shows an ALD temperature window in the range 280–300 °C with a growth rate of ∼0.3 Å per cycle. On the other hand, using oxygen as the reactant gas in the MOCVD of Ga<SUB>2</SUB>O<SUB>3</SUB>, films are grown in the temperature range 450–625°C with the apparent activation energy of 225.5 kJ mol<SUP>−1</SUP>. This study shows that DMGIP can be utilized as a new source for the preparation of Ga<SUB>2</SUB>O<SUB>3</SUB> thin films.</P>
Formation of silicon sheet on a rotating substrate.
Lee, Jaewoo,Lee, Changbum,Kim, Joonsoo,Jang, Bo-Yun,Ahn, Youngsoo,Yoon, Wooyoung American Scientific Publishers 2012 Journal of Nanoscience and Nanotechnology Vol.12 No.4
<P>A spin casting process to fabricate polycrystalline silicon sheets for use as solar cell wafers is presented and the parameters that control the sheet thickness are investigated. The computational model for the spin casting is proposed in order to understand the melt flow and solidification behaviors in the mold. The effect of the rotating speed of the mold and substrate morphology on the silicon sheets is studied via computer simulations, and the simulation results are compared with the experimental results. The numerical study of the fluidity and solidification behavior of the silicon predicted that the formation of rectangular sheets via spin casting is feasible, and the subsequent experiment confirmed this prediction. Using a square mold, rectangular silicon sheets can be produced under appropriate experimental conditions. Microstructural analyses verified the presence of long columnar structures on the sheets.</P>